Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov;17(7):505-7.
doi: 10.1016/j.ejim.2006.05.002.

Parvovirus B19 Reactivation Presenting as Neutropenia After Rituximab Treatment

Affiliations

Parvovirus B19 Reactivation Presenting as Neutropenia After Rituximab Treatment

A Klepfish et al. Eur J Intern Med. .

Abstract

A patient with primary biliary cirrhosis and associated refractory immune thrombocytopenic purpura was treated with 4 weekly courses of rituximab, a monoclonal antibody targeting B-cell surface antigen CD20. Her thrombocyte count and even cholestatic liver function tests improved. However, 17 weeks after rituximab treatment, she developed severe neutropenia (absolute neutrophil count 0.23x10(3)/mul) and recurrent thrombocytopenia with abnormal bone marrow of all three lineages. Although delayed-onset neutropenia has been reported after rituximab, reactivated viral infections have also been encountered. Parvovirus B19 was suspected and confirmed as the cause of neutropenia in our patient. The patient was supported by GCSF treatment and recovered uneventfully after several weeks. Neutropenia after rituximab can also be the predominant manifestation of reactivated parvovirus B19 infection and have a favorable prognosis.

Similar articles

See all similar articles

Cited by 2 articles

LinkOut - more resources

Feedback